UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001394208 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE O TEST Submission Contact Information

Name Phone **E-Mail Address**

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			SOCULUTIOC
Common	Jefferies LLC 520 Madison Ave, 4th Fl New York NY 10022	15000	492000.00	58350000	07/03/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Date you

Title of the Class

Nature of Acquisition Acquired Transaction

Name of Person from Whom Acquired

Is Date this Donor Gift? Acquired а

Amount of Securities Acquired

Date of Payment

Nature of Payment *

001-40928 662 ENCINITAS BLVD., STE, 250 **ENCINITAS CALIFORNIA** 92024 (858) 945-2393

Ventyx Biosciences, Inc.

Krueger Christopher W

Officer

Common	05/01/2020 Stock Option Grant	Ventyx Biosciences	13911	05/01/2020 N/A
Common	09/18/2021 Stock Option Grant	Ventyx Biosciences	1009	09/18/2021 N/A
Common	09/18/2021 Stock Option Grant	Ventyx Biosciences	80	09/18/2021 N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher W. Krueger 662 Encinitas Blvd, Suite 250 Encinitas CA 92024	Common	04/03/2023	15000	493165.65
Christopher W. Krueger 662 Encinitas Blvd, Suite 250 Encinitas CA 92024	Common	05/03/2023	15000	579699.15
Christopher W. Krueger 662 Encinitas Blvd, Suite 250 Encinitas CA 92024	Common	06/05/2023	15000	515379.00

144: Remarks and Signature

Remarks	
Date of Notice	07/03/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/28/2022
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Erik Clancy

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)